United States $1 Trillion Biopharmaceutical Giant Eli Lilly Makes 3 Vaccine Company Acquisitions for $3.8 Billion (Include Contingents) to Build Infectious Disease Portfolio, Acquiring 1) Curevo for $1.5 Billion, 2) LimmaTech Biologics for $780 Million & 3) Vaccine Company for $1.55 Billion in All-Cash Deals, Eli Lilly Founded in 1876, Eli Lilly Current Market Value at $1 Trillion, Share Price +3.1% YTD, +54.0% Last 12 Months & +457.2% Last 5 Years
29th May 2026 | Hong Kong
United States biopharmaceutical giant Eli Lilly ($1 trillion market value) has made 3 vaccine company acquisitions for $3.83 billion (Include contingents) to build infectious disease portfolio, acquiring 1) Curevo for $1.5 billion, 2) LimmaTech Biologics for $780 million & 3) Vaccine Company for $1.55 billion in all-cash deals. Eli Lilly was founded in 1876. Eli Lilly current market value at $1 trillion, share price +3.1% YTD, +54.0% last 12 months & +457.2% last 5 years. Curevo – Curevo is a privately held, clinical stage biotechnology company based near Seattle dedicated to reducing the burden of infectious disease by developing vaccines with improved tolerability and accessibility. Curevo’s lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain. LimmaTech Biologics – LimmaTech Biologics is developing vaccines against bacterial pathogens for which rising antimicrobial resistance is steadily closing therapeutic options, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis. The company’s proprietary platform is designed to generate broad, durable immune responses against complex bacterial targets by targeting the toxins and superantigens that drive disease. LimmaTech’s lead program, LTB-SA7, is in Phase 1 development as a vaccine against S. aureus, the leading cause of surgical-site infection. Vaccine Company – Vaccine Company is developing proprietary In Vivo Nanoparticle (IVN) technologies designed to enable the antigen display known to elicit durable immune responses associated with virus-like particle vaccines, while avoiding the manufacturing burden of traditional VLP production. The company is advancing a broad preclinical pipeline spanning multiple viral pathogens; the lead program applies this technology to Epstein-Barr Virus (EBV) with a five-antigen Phase 1-ready candidate. Eli Lilly – Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people.
“ United States $1 Trillion Biopharmaceutical Giant Eli Lilly Makes 3 Vaccine Company Acquisitions for $3.8 Billion (Include Contingents) to Build Infectious Disease Portfolio, Acquiring 1) Curevo for $1.5 Billion, 2) LimmaTech Biologics for $780 Million & 3) Vaccine Company for $1.55 Billion in All-Cash Deals, Eli Lilly Founded in 1876, Eli Lilly Current Market Value at $1 Trillion, Share Price +3.1% YTD, +54.0% Last 12 Months & +457.2% Last 5 Years “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
United States $1 Trillion Biopharmaceutical Giant Eli Lilly Makes 3 Vaccine Company Acquisitions for $3.8 Billion (Include Contingents) to Build Infectious Disease Portfolio, Acquiring 1) Curevo for $1.5 Billion, 2) LimmaTech Biologics for $780 Million & 3) Vaccine Company for $1.55 Billion in All-Cash Deals, Eli Lilly Founded in 1876, Eli Lilly Current Market Value at $1 Trillion, Share Price +3.1% YTD, +54.0% Last 12 Months & +457.2% Last 5 Years
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
